September 16, 2025- Medtronic plc announced the initiation of a pivotal study evaluating the use of elevated and personalized cardiac pacing rates for the treatment of patients with Heart Failure with preserved Ejection Fraction (ELEVATE-HFpEF, NCT06678841). Physicians routinely use pacing therapy to treat patients whose hearts beat too slowly (bradycardia). This study, however, will investigate a potential novel treatment for patients with HFpEF by using conduction system pacing to improve patient outcomes and heart failure symptoms. Medtronic intends to use the study results to pursue a new pacing indication for patients with HFpEF who currently have limited clinically proven treatments.
HFpEF is a condition when the cardiac muscles stiffen and do not relax properly, causing diminished blood flow and an inability to meet the body’s needs.